Tonix Pharmaceuticals Holdings Corp (NASDAQ: TNXP) stock dropped 6.56% after the company announced plans to develop TNX-102 SL as a possible Long COVID Syndrome treatment. Long COVID is known as the Post-Acute Sequelae of COVID-19. Tonix to meet FDA in Q3 to discuss TNX-102 SL in Long COVID treatment The […]